Detection of Circulating Tumour Cells in Urothelial Cancers and Clinical Correlations: Comparison of Two Methods

Figure 3

Circulating tumour cell (CTC) distribution in the different clinical settings. The number of CTC per 5 mL of blood, detected by ScreenCell approach, is reported for each clinical setting (patients with muscle-invasive nonmetastatic bladder cancer, ; patients with bladder cancer, under first-line, , or second-line, , therapy) at each time point analyzed: baseline (, green dots), after the first (, yellow dots), and after the second (, red dots) cycle of therapy.